Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000338279

Medchemexpress LLC BNC375 | 1557240-80-8 | 99.6% | 10 MG
SDP

Catalog No. 5000338279
Encompass_Preferred

BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. It exhibits good CNS-agent like properties and clinical candidate potential. BNC375 significantly potentiates the acetylcholine signal without changing the rapid receptor desensitization. In vivo, BNC375 (0.003-10.0 mg/kg, administered orally) exhibits a Minimum Effective Dose (MED) of 0.03 mg/kg, achieving full reversal of scopolamine-induced impairment at 1.0 mg/kg in a mouse T-maze model. It has a plasma half-life (t1/2) of 1.2 hours.

  • Potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs.
  • Exhibits good CNS-agent like properties.
  • Clinical candidate potential.
  • Significantly potentiates acetylcholine signal.
  • Achieves full reversal of scopolamine-induced impairment in mouse T-maze model.
  • Plasma half-life (t1/2) of 1.2 hours.

Catalog No. 50-003-38279 Supplier Medchemexpress LLC Supplier No. HY12857510MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. It exhibits good CNS-agent like properties and clinical candidate potential. BNC375 significantly potentiates the acetylcholine signal without changing the rapid receptor desensitization. In vivo, BNC375 (0.003-10.0 mg/kg, administered orally) exhibits a Minimum Effective Dose (MED) of 0.03 mg/kg, achieving full reversal of scopolamine-induced impairment at 1.0 mg/kg in a mouse T-maze model. It has a plasma half-life (t1/2) of 1.2 hours.

  • Potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs.
  • Exhibits good CNS-agent like properties.
  • Clinical candidate potential.
  • Significantly potentiates acetylcholine signal.
  • Achieves full reversal of scopolamine-induced impairment in mouse T-maze model.
  • Plasma half-life (t1/2) of 1.2 hours.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.